RXRuixiang Xia

Ruixiang Xia

*This is an algorithmically generated author record based on publicly available information.

Ruixiang Xia has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Qing Zhou

    Laboratory of Molecular Biology and Department of Biochemistry, Key Laboratory of Gene Research of Anhui, Hefei, Anhui 230032, P.R. China

    2 shared publications
  • Rui Shi

    Clincal Center of Tumor Therapy, The Lu'an People's Hospital, Lu'an, Anhui 237005, P.R. China

    1 shared publication
  • Shaolong Chen

    Laboratory of Molecular Biology and Department of Biochemistry, Key Laboratory of Gene Research of Anhui, Hefei, Anhui 230032, P.R. China

    1 shared publication
  • Sumei Zhang

    Anhui Medical University

    1 shared publication
  • Xiang Wei

    Laboratory of Molecular Biology and Department of Biochemistry, Key Laboratory of Gene Research of Anhui, Hefei, Anhui 230032, P.R. China

    1 shared publication
  • Yuan Wang

    Anhui Medical University

    1 shared publication

Latest Publications

  • Open Access

    All-trans retinoic acid inhibits the proliferation of SGC7901 cells by regulating caveolin-1 localization via the ERK/MAPK signaling pathway

    by Sumei Zhang, Rui Shi, Shaolong Chen, Xiang Wei, Qing Zhou, Yuan Wang

    Caveolin-1 is a scaffold protein of caveolae in the mucosa of the gastrointestinal tract and acts as a tumor modulator by interacting with cell adhesion molecules and signaling receptors. Caveolin-1 stabilizes cell-cell and cell-matrix contacts and is a hallmark of a number of different types of human cancer, including gastric cancer. All-trans retinoic acid (ATRA), a derivative of vitamin A, has been demonstrated to exhibit tumor inhibitory effects in acute leukemia and certain types of solid tumor. In the present study, treatment with ATRA was demonstrated to inhibit the proliferation of gastric cancer cell line SGC7901, in a time- and dose-dependent manner. The markedly increased membrane localization of caveolin-1 was observed in the cells that were treated with 10 µmol/l ATRA for > 48 h. In addition, it was observed that treatment with ATRA was able to regulate the level of phosphorylation of extracellular signal-regulated kinase (ERK). Therefore, the SGC7901 cells were treated with a specific agonist of ERK/mitogen-activated protein kinase (MAPK) investigate whether ATRA mediated its effects via the ERK/MAPK signaling pathway. The results of the present study demonstrated that ATRA-induced increase in membrane localization of caveolin-1 was reversed by treatment with a specific agonist of ERK/MAPK. Together, these results suggest that ATRA exhibits anti-gastric cancer effects. ATRA may regulate the membrane localization of caveolin-1 in order to inhibit the proliferation of SGC7901 cells. These effects of ATRA may be mediated by inhibiting the activation of ERK/MAPK signaling pathway. These results contribute to the current knowledge on the potential use of ATRA as therapy for solid tumors and provide further insight into the potential molecular mechanisms of ATRA action.


  • Endocan, a potential prognostic and diagnostic biomarker of acute leukemia

    by Zhe Xu, Sumei Zhang, Qing Zhou, Yuan Wang, Ruixiang Xia

    Recent evidence indicated that endocan may be a potential cell marker and a new target for cancers including acute leukemia since the serum endocan level in patients with acute leukemia was associated with the status of the disease, i.e., endocan was higly expressed in untreated acute leukemia, but decreased after chemotherapy and increased again during bone marrow regeneration. The present study showed that there was high level expression of endocan in cytoplasm of bone marrow blasts of patients with acute myeloid leukemia or acute lymphoblastic leukemia. The expression level of endocan was significantly decreased when the patients underwent remission after chemotherapy and re-bounces back when the acute leukemia relapsed. No obvious change in expression of endocan was observed before and after chemotherapy if the patients showed no remission after chemotherapy. (N-(4-Hydroxyphenyl) retinamide), a potent anti-angiogenic agent, could not only down-regulate the expression of vascular epithelial growth factor, but also decrease endocan transcription and expression in NB4 cells, a human acute promyelocytic leukemia cell line. These observations suggest that endocan could act as a predictor for the severity and the prognosis of acute leukemia. The findings could be used as the basis for future targeted therapy directed against bone marrow angiogenesis in acute leukemia treatment.